Efficacy and Safety of LP-003 in Patients With CSU Who Remain Symptomatic Despite Antihistamine (H1) Treatment

NCT06228560 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

202

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Spontaneous Urticaria

Interventions

BIOLOGICAL: LP-003
BIOLOGICAL: Placebo
BIOLOGICAL: Omalizumab

Sponsor

Longbio Pharma